Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.
about
Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic ReviewThe effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysisInsulin resistance in chronic kidney disease: a systematic review.Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.Active vitamin D treatment for reduction of residual proteinuria: a systematic review.Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D studyStirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?Vitamin D and the cardiovascular system: an overview of the recent literature.Shining light on vitamin D trials in chronic kidney disease.Vitamin D, a modulator of musculoskeletal health in chronic kidney disease.Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis.Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD.Vitamin D and cardio-metabolic disease.Vitamin D deficiency: consequence or cause of CKD?Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients.Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α.
P2860
Q26774371-133DBB0F-B617-44B8-99FC-F5C6F9104A53Q27021893-B119C895-2750-4E8A-B9F4-9D5DDE0791B4Q30244271-621CFDC4-CF6C-4AF5-9B85-AE8D37F44471Q34868253-861C4F29-4CE6-4957-BA99-FA8021D7C61CQ34912750-CED34744-D4F6-4B0B-BE62-9D4BFBCB9E1DQ34967905-DFFA4C6D-3C3F-4915-9D96-04CC750000A9Q37729792-63EFBBF3-D1EC-492B-BEA6-4D216628845EQ38152318-E1BDD8D7-5FC7-4E15-A579-F4A11570EACBQ38818509-8A5E5362-279C-4473-A25B-A6F27DF866D4Q39413414-AB97C003-B105-480B-8A95-87B18030F6E9Q40277283-25E89B2D-3789-4779-A742-916F73E454B4Q40974270-95C81DFA-7F8D-4BD5-8ADE-62B85E433250Q42159607-7B7184E0-C830-4CBB-A024-A02B3340CF00Q42921238-3F81C689-352B-4D8A-858C-60C3041B8AA6Q46673943-7FEBFD44-E3B6-4645-890B-4BEA8C97AA9DQ51321869-9661045B-FFA3-4370-8558-C84E45E1166DQ51823258-B323A9B0-82B8-44DC-8459-B79DCD9A22BBQ55279804-55B82F37-9E77-4B5B-9A39-9C95679C6D1C
P2860
Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@ast
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@en
type
label
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@ast
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@en
prefLabel
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@ast
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@en
P2093
P2860
P50
P356
P1433
P1476
Paricalcitol does not improve ...... ge 3-4 chronic kidney disease.
@en
P2093
Ian H de Boer
Jonathan Himmelfarb
Kristina M Utzschneider
P2860
P2888
P304
P356
10.1038/KI.2012.311
P407
P577
2012-08-22T00:00:00Z